Elevated level of the soluble receptor for advanced glycation end-products involved in sarcopenia: an observational study

Abstract

Background The soluble receptor for advanced glycation end products (sRAGE) has been proposed to serve as a marker for disease severity, but its role in sarcopenia, an age-related progressive loss of muscle mass and function, remains elusive. This study examines the association between sRAGE and sarcopenia. Methods A total of 314 community-dwelling elderly adults who had their health examination at Tri-Service General Hospital from 2017 to 2019 underwent protein analysis with enzyme-linked immunosorbent assay. The relationship with sarcopenia and its detailed information, including components and diagnosis status, were examined using linear and logistic regressions. Results As for sarcopenia components, low muscle mass (β\u2009=\u2009162.8, p \u2009=\u20090.012) and strength (β\u2009=\u2009181.31, p \u2009=\u20090.011) were significantly correlated with sRAGE, but not low gait speed ( p \u2009=\u20090.066). With regard to disease status, confirmed sarcopenia (β\u2009=\u2009436.93, p \u2009<\u20090.001), but not probable ( p \u2009=\u20090.448) or severe sarcopenia ( p \u2009=\u20090.488), was significantly correlated with sRAGE. In addition, females revealed a stronger association with sRAGE level by showing significant correlations with low muscle mass (β\u2009=\u2009221.72, p \u2009=\u20090.014) and low muscle strength (β\u2009=\u2009208.68, p \u2009=\u20090.043). Conclusions sRAGE level showed a positive association with sarcopenia, illustrating its involvement in the evolution of sarcopenia. This association is more evident in female groups, which may be attributed to the loss of protection from estrogen in postmenopausal women. Utilizing sRAGE level as a prospective marker for sarcopenia deserves further investigation in future studies.